Sulforaphane Inhibits Colorectal Cancer Progression via PI3K/AKT/mTOR and HIF-1a Suppression with Enhanced Efficacy under Hypoxia

Sulforaphane (SFN) exhibits anticancer activity across diverse tumor models, yet its role under hypoxia—a hallmark of the colorectal cancer microenvironment—remains incompletely defined. In this study, colorectal cancer cells were cultured under hypoxic conditions and treated with SFN or a combination of SFN and 5-fluorouracil (5-FU). RNA-seq profiling was performed to characterize transcriptional alterations associated with SFN activity and SFN-mediated reversal of hypoxia-induced 5-FU resistance. The dataset includes paired-end raw FASTQ files, supporting further investigation into hypoxia-related signaling networks, including PI3K/AKT/mTOR and HIF-1a pathways. Overall design: This study includes three groups of colorectal cancer cells cultured under hypoxia: (1) hypoxia control, (2) hypoxia + sulforaphane (SFN), and (3) hypoxia + SFN + 5-fluorouracil (5-FU). Each group contains three biological replicates. Total RNA was extracted after 48 h of treatment and sequenced using Illumina paired-end RNA-seq. Raw FASTQ files and corresponding md5 checksum files are provided.